HUP9802199A1 - Poliszacharid antigén-vivőprotein konjugátumot és szabad vivőproteint tartalmazó oltóanyag és alkalmazása - Google Patents

Poliszacharid antigén-vivőprotein konjugátumot és szabad vivőproteint tartalmazó oltóanyag és alkalmazása

Info

Publication number
HUP9802199A1
HUP9802199A1 HU9802199A HUP9802199A HUP9802199A1 HU P9802199 A1 HUP9802199 A1 HU P9802199A1 HU 9802199 A HU9802199 A HU 9802199A HU P9802199 A HUP9802199 A HU P9802199A HU P9802199 A1 HUP9802199 A1 HU P9802199A1
Authority
HU
Hungary
Prior art keywords
carrier protein
vaccine
polysaccharide antigen
free
conjugate
Prior art date
Application number
HU9802199A
Other languages
English (en)
Inventor
Pierre Hauser
Moncef Mohamed Slaoui
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9802199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en
Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en
Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of HUP9802199A1 publication Critical patent/HUP9802199A1/hu
Publication of HUP9802199A3 publication Critical patent/HUP9802199A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A találmány vivőprőteinhez kötött pőliszacharid antigént tartalmazókőmbinált őltóanyag, ahől a vevőprőtein szabad antigénként is jelenvan, azzal jellemezve, hőgy a kötött főrmában a pőliszacharidvivőprőtein arány 1 : 0,3 és 1 : 1 között van. ŕ
HU9802199A 1995-06-07 1996-06-04 Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of HUP9802199A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47263995A 1995-06-07 1995-06-07
GBGB9512827.8A GB9512827D0 (en) 1995-06-23 1995-06-23 Vaccines
GBGB9513443.3A GB9513443D0 (en) 1995-07-01 1995-07-01 Vaccines
GBGB9525657.4A GB9525657D0 (en) 1995-12-15 1995-12-15 Vaccines

Publications (2)

Publication Number Publication Date
HUP9802199A1 true HUP9802199A1 (hu) 1999-01-28
HUP9802199A3 HUP9802199A3 (en) 1999-07-28

Family

ID=27451300

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802199A HUP9802199A3 (en) 1995-06-07 1996-06-04 Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of

Country Status (18)

Country Link
EP (2) EP0831901B2 (hu)
JP (2) JP4233113B2 (hu)
AT (2) ATE400295T1 (hu)
AU (1) AU695720B2 (hu)
BR (1) BR9608612A (hu)
CA (1) CA2221511C (hu)
CZ (1) CZ390297A3 (hu)
DE (2) DE69637597D1 (hu)
DK (1) DK1090642T3 (hu)
ES (2) ES2308962T3 (hu)
HU (1) HUP9802199A3 (hu)
IL (1) IL122431A0 (hu)
NO (1) NO975555L (hu)
NZ (1) NZ311000A (hu)
PT (1) PT1090642E (hu)
SI (1) SI1090642T1 (hu)
TR (1) TR199701547T1 (hu)
WO (1) WO1996040242A1 (hu)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
ES2308962T3 (es) * 1995-06-07 2008-12-16 Glaxosmithkline Biologicals S.A. Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre.
WO1998000167A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
JP2002502830A (ja) 1998-02-05 2002-01-29 ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン タンパク質−多糖コンジュゲートおよびワクチンの製造中に遊離タンパク質を除去するための、接近が制限された媒介材料を用いる簡素化された方法
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
BR0009163A (pt) 1999-03-19 2001-12-26 Smithkline Beecham Biolog Vacina
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
PT2332581E (pt) 2001-01-23 2015-10-16 Sanofi Pasteur Inc Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
ATE492288T1 (de) 2002-10-11 2011-01-15 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
BR0315767A (pt) 2002-11-01 2005-09-06 Glaxosmithkline Biolog Sa Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP4827726B2 (ja) 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群に対する注射可能ワクチン
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
CN103357002A (zh) 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
US8431136B2 (en) 2005-06-27 2013-04-30 Glaxosmithkline Biologicals S.A. Immunogenic composition
RU2457858C2 (ru) 2005-09-01 2012-08-10 Новартис Вэксинес Энд Дайэгностикс Гмбх Унд Ко Кг Множественная вакцинация, включающая менингококки серогруппы с
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2670231T3 (es) 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regímenes para inmunización con conjugados meningocócicos
EP2066344B2 (en) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inactivated Poliovirus combination vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
AU2009309416B2 (en) 2008-10-27 2015-05-28 Glaxosmithkline Biologicals S.A. Purification method
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
EP3199177A1 (en) 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
ES2707778T3 (es) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
EP2612148B1 (en) 2010-09-04 2019-06-12 GlaxoSmithKline Biologicals SA Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
RU2013144207A (ru) 2011-03-02 2015-04-10 Новартис Аг Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
GB201106340D0 (en) * 2011-04-14 2011-06-01 Isis Innovation Composition
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
CN104717977A (zh) 2012-10-03 2015-06-17 诺华股份有限公司 免疫原性组合物
AU2013328548A1 (en) 2012-10-12 2015-05-07 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
CN105007935A (zh) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 用于保护免于白喉和/或破伤风的缀合物
RU2015131033A (ru) * 2013-01-04 2017-02-09 Оби Фарма, Инк. Вакцины с повышенной плотностью размещения углеводного антигена и новый сапониновый адъювант
CN104174019A (zh) * 2014-09-23 2014-12-03 成都康华生物制品有限公司 四价脑膜炎球菌多糖载体蛋白结合疫苗
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
JP6944946B2 (ja) 2016-10-20 2021-10-06 Ｋｍバイオロジクス株式会社 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
CA3201450A1 (en) 2020-11-13 2022-05-19 Glaxosmithkline Biologicals Sa Bacterial protein carriers and conjugation methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
ES2071288T3 (es) * 1989-12-14 1995-06-16 Ca Nat Research Council Vacuna mejorada de conjugado de polisacarido de meningococos.
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
SG47725A1 (en) * 1992-10-27 1998-04-17 American Cyanamid Co Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
ES2308962T3 (es) * 1995-06-07 2008-12-16 Glaxosmithkline Biologicals S.A. Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre.

Also Published As

Publication number Publication date
AU6222196A (en) 1996-12-30
ATE205724T1 (de) 2001-10-15
JP4233113B2 (ja) 2009-03-04
IL122431A0 (en) 1998-06-15
DE69615362T3 (de) 2006-07-20
ES2164251T5 (es) 2006-06-01
HUP9802199A3 (en) 1999-07-28
EP1090642A3 (en) 2001-08-22
NO975555D0 (no) 1997-12-02
EP0831901A1 (en) 1998-04-01
EP1090642B1 (en) 2008-07-09
EP1090642A2 (en) 2001-04-11
ATE400295T1 (de) 2008-07-15
CA2221511C (en) 2013-01-08
EP0831901B1 (en) 2001-09-19
PT1090642E (pt) 2008-09-09
EP1090642B8 (en) 2010-08-11
CZ390297A3 (cs) 1998-05-13
EP0831901B2 (en) 2005-12-07
MX9709732A (es) 1998-10-31
DK1090642T3 (da) 2008-09-22
AU695720B2 (en) 1998-08-20
JP4653131B2 (ja) 2011-03-16
TR199701547T1 (xx) 1998-03-21
BR9608612A (pt) 1999-05-04
SI1090642T1 (sl) 2008-12-31
DE69637597D1 (de) 2008-08-21
DE69615362D1 (de) 2001-10-25
ES2308962T3 (es) 2008-12-16
NZ311000A (en) 1999-04-29
CA2221511A1 (en) 1996-12-19
DE69615362T2 (de) 2002-06-13
JPH11507026A (ja) 1999-06-22
NO975555L (no) 1998-01-09
WO1996040242A1 (en) 1996-12-19
ES2164251T3 (es) 2002-02-16
JP2007186524A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
HUP9802199A1 (hu) Poliszacharid antigén-vivőprotein konjugátumot és szabad vivőproteint tartalmazó oltóanyag és alkalmazása
EP1027061A4 (en) IMIN-FORMING POLYSACCHARIDES, THEIR PRODUCTION AND USE AS ADDITIVES AND IMMUNO-STIMULATING AGENTS
HRP20000443B1 (en) Prevention and treatment of amyloidogenic disease
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
MY125202A (en) Vaccine
PL323862A1 (en) Vaccines containing conjugated modified meningococcal polysaccharide
CY1106206T1 (el) Φαρμακευτικη συνθεση πepιεχουσα φενοφιβρατη και μεθοδος παρασκευης της
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
BR9809656A (pt) Composição imunopotencializante
DE69824023D1 (de) Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
EP0770624A3 (en) Peptide capable of inducing immune response to human gastric cancer and agent containing it for preventing or treating human gastric cancer
SE9501512D0 (sv) Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
DE59509948D1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
RU95104325A (ru) Коньюгаты антител с улучшенными свойствами
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
AU622548B2 (en) Novel tumor-associated antigen, antibodies, compositions and uses therefor
KR960010021A (ko) 펩타이드 항원을 함유하는 리포좀